The FDA is reconsidering how it regulates compounded peptides and the implications are significant for access, safety, and clarity. Right now, the peptide landscape includes approved therapeutics, compounds in active clinical Peptides for Weight Loss NYC: GLP 1, CJC 1295, AOD 9604 Explained Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of All Sterile Compounded Drug Products Due to A Lack of Sterility Assurance FDA AOD9604 Vitalis Biosciences